Novacyt — M&A Activity 2024

Sep 20, 2024

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED INTENTIONS

FOR IMMEDIATE RELEASE

20 September 2024

Novacyt S.A. ("Novacyt", the "Company" or the "Group")

Rule 19.6(c) confirmation in respect of post-offer intention statements made in relation to Yourgene Health plc ("Yourgene")

Novacyt announces that, further to the completion of its recommended cash offer for the entire issued and to be issued share capital of Yourgene, which was implemented by way of a scheme of arrangement under Part 26 of the Companies Act 2006 and which became effective on 8 September 2023, it has duly confirmed in writing to The Panel on Takeovers and Mergers in accordance with the requirements of Rule 19.6(c) of the Code that Novacyt has complied with their respective post-offer intention statements made pursuant to Rules 2.7(c)(viii) and 24.2 of the Code, as detailed in its announcement of 3 July 2023 and scheme document published on 27 July 2023.

Contacts

Novacyt SA Lyn Rees, Chief Executive Officer Steve Gibson, Chief Financial Officer	https://novacyt.com/investors Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44 (0)20 3470 0470 Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker) +44 (0)20 7260 1000 Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor)	+33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit	r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7796 794 663 / +44 (0)7980 541 893 +44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

• Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: • Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
  • Precision Medicine: DPYD genotyping assay
  • Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
• Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
  • Ranger® Technology: automated DNA sample preparation and target enrichment technology

MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only Range of services for the research industry:

• Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
• Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com